reports
- Yun Zhong
INVITE: Wedbush Analyst Call On PTGX & JNJ Situation Overview
We do not find the reported M&A discussion between JNJ and PTGX to be surprising given the existing collaboration on icotrokinra, which after potential FDA and EMA approvals in 2026 for PsO and with ongoing Ph3 programs for both IBD and PsA should target an over $5B market based on JNJ manageme
- Yun Zhong
Acquisition By JNJ Makes Sense But Valuation Is The Question
JNJ Only Needs to Pay at Most 10% Royalties on Icotrokinra to PTGX. Icotrokinra is included in a worldwide license and collaboration agreement that PTGX and JNJ initially entered into in May. '17 to co-develop and co-commercialize IL-23R antagonist compounds for various indications. A major milesto
- Wedbush Research
WDC WESTERN DIGITAL CORPORATION
TSLA TESLA INC
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
AXTI AXT INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
PTGX PROTAGONIST THERAPEUTICS
ANAB ANAPTYSBIO INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
STTK SHATTUCK LABS
STX SEAGATE TECHNOLOGY HLDGS PLC
GFS GLOBALFOUNDRIES INC
SYRE SPYRE THERAPEUTICS INC.
DBD DIEBOLD NIXDORF INCORPORATED
- David Nierengarten
- Dennis Pak
- Martin Fan
- Yun Zhong
- Yun Zhong
KOL Comments Continue To Support Icotrokinra's Strong Potential In IBD
Icotrokinra Demonstrated a Clear Dose Response, across all efficacy endpoints except symptomatic remission (stool frequency subscore of 0 or 1 and rectal bleeding of 0), which showed continued improvement in all cohorts from treatment initiation through week 12. Additionally, the safety profile is
- Wedbush Research
TSLA TESLA INC
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
NFLX NETFLIX INC.
WVE WAVE LIFE SCIENCES
PTGX PROTAGONIST THERAPEUTICS
ANAB ANAPTYSBIO INC.
ROKU ROKU INC. CLASS A
MDB MONGODB INC. CLASS A
AMZN AMAZON.COM INC.
MSFT MICROSOFT CORPORATION
ACET ADICET BIO INC
STTK SHATTUCK LABS
BEAM BEAM THERAPEUTICS
PLTR PALANTIR TECHNOLOGIES
SNOW SNOWFLAKE INC. CLASS A
TTD THE TRADE DESK
PRME INC.
SYRE PRIME MEDICINE INC
JBIO SPYRE THERAPEUTICS INC.
JADE BIOSCIENCES INC
- David Nierengarten
- Dennis Pak
- Martin Fan
- Yun Zhong
- Wedbush Research
- David Nierengarten
- Dennis Pak
- Martin Fan
- Yun Zhong
- David Nierengarten
- Dennis Pak
- Geoffrey Von Der Ahe
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Yun Zhong
BCRX BIOCRYST PHARMACEUTICALS INC.
ACRS ACLARIS THERAPEUTICS INC.
WVE WAVE LIFE SCIENCES
PTGX PROTAGONIST THERAPEUTICS
ANAB ANAPTYSBIO INC.
RCUS ARCUS BIOSCIENCES
ARVN ARVINAS HOLDING
STTK SHATTUCK LABS
BEAM BEAM THERAPEUTICS
NUVB NUVATION BIO INC (A)
NUVL NUVALENT INC
PRME PRIME MEDICINE INC
Protagonist Therapeutics Inc: 1 director
A director at Protagonist Therapeutics Inc sold 4,000 shares at 64.250USD and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...
- Wedbush Research
- Yun Zhong
- Wedbush Research
XNCR XENCOR INC.
WDC WESTERN DIGITAL CORPORATION
TSLA TESLA INC
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
PANW PALO ALTO NETWORKS INC.
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
KURA KURA ONCOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
CYBR CYBERARK SOFTWARE LTD.
CXW CORECIVIC INC.
AXTI AXT INC.
ACRS ACLARIS THERAPEUTICS INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
BLDR BUILDERS FIRSTSOURCE INC.
PTGX PROTAGONIST THERAPEUTICS
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
MDB MONGODB INC. CLASS A
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
ZS ZSCALER INC.
CRWD CROWDSTRIKE HOLDINGS INC. CLASS A
SMCI SUPER MICRO COMPUTER
STTK INC.
NUVB SHATTUCK LABS
STX NUVATION BIO INC (A)
ATXS SEAGATE TECHNOLOGY HLDGS PLC
GFS ASTRIA THERAPEUTICS INC
MLTX GLOBALFOUNDRIES INC
SYRE MOONLAKE IMMUNOTHERAPEUTICS
ORKA SPYRE THERAPEUTICS INC.
ORUKA THERAPEUTICS INC
- Yun Zhong
- David Nierengarten
- Dennis Pak
- Geoffrey Von Der Ahe
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Yun Zhong
- David Nierengarten
- Dennis Pak
- Martin Fan
- Yun Zhong
- Wedbush Research
WDC WESTERN DIGITAL CORPORATION
TSLA TESLA INC
TPH TRI POINTE HOMES INC.
TOL TOLL BROTHERS INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
LEN LENNAR CORPORATION CLASS A
INTC INTEL CORPORATION
AXTI AXT INC.
ACRS ACLARIS THERAPEUTICS INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
TMHC TAYLOR MORRISON HOME CORPORATION
MHO M/I HOMES INC.
PTGX PROTAGONIST THERAPEUTICS
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
SMCI SUPER MICRO COMPUTER
STX INC.
ATXS SEAGATE TECHNOLOGY HLDGS PLC
GFS ASTRIA THERAPEUTICS INC
GMTX GLOBALFOUNDRIES INC
MLTX GEMINI THERAPEUTICS INC
APGE MOONLAKE IMMUNOTHERAPEUTICS
ORKA APOGEE THERAPEUTICS INC
AVTX ORUKA THERAPEUTICS INC
AVALO THERAPEUTICS INC
- David Nierengarten
- Dennis Pak
- Geoffrey Von Der Ahe
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Yun Zhong
AMREP Reports First Quarter Fiscal 2026 Results
AMREP Reports First Quarter Fiscal 2026 Results HAVERTOWN, Pa., Sept. 09, 2025 (GLOBE NEWSWIRE) -- AMREP Corporation (NYSE:AXR) today reported net income of $4,692,000, or $0.87 per diluted share, for its 2026 fiscal first quarter ended July 31, 2025 compared to net income of $4,064,000, or $0.76 per diluted share, for the same period of the prior year. Revenues were $17,851,000 for the first quarter of 2026 and $19,091,000 for the first quarter of 2025. More information about the Company’s financial performance may be found in AMREP Corporation’s financial statements on Form 10-Q which ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.